| Document |
Document Title |
|
WO/2018/222890A1 |
This invention provides expressible polynucleotides, which can express a target protein or polypeptide. Synthetic mRNA constructs for producing a protein or polypeptide can contain one or more 5' UTRs, where a 5' UTR may be expressed by ...
|
|
WO/2018/221498A1 |
The present invention relates to a method of manufacturing a protein fiber that includes a step for introducing a spinning dope that contains protein and a first dissolving solvent into a solidifying bath liquid and solidifying the prote...
|
|
WO/2018/223014A1 |
Provided herein are DNA-glycan conjugates that include a glycan and a covalently attached polynucleotide. The polynucleotide includes a plurality of modules. Each module includes a nucleotide string, and the plurality of modules includes...
|
|
WO/2018/220210A1 |
This invention relates to recombinant lentiviral vectors, compositions thereof, the use of the vectors or the compositions thereof, kits of parts comprising said vectors or compositions thereof and a catalytically active Cas9 or Cpf1 pro...
|
|
WO/2018/220579A1 |
A coffee plant comprising a genome comprising a loss of function mutation in a nucleic acid sequence encoding alpha-D-galactosidase. Also provided is a method of increasing extractability of solids from coffee beans. In addition there is...
|
|
WO/2018/220581A1 |
A banana plant comprising a genome comprising a loss of function mutation in a nucleic acid sequence encoding a component in an ethylene biosynthesis pathway of the banana is provided. Also provides is a method of increasing shelf-life o...
|
|
WO/2018/219214A1 |
Disclosed is a PCR-HRM detection method for rapidly identifying a PRRSV vaccine strain, i.e. GDr180 strain, and other virulent strains. The method of the present invention is based on PCR in combination with HRM, comprising a first round...
|
|
WO/2018/219264A1 |
A long-chain non-coding RNA marker lncLOX5-1 for early diagnosis and prognosis of prostatic cancer and use thereof. Said lncLOX5-1 has the characteristics of high accuracy, high specificity, and high sensitivity, being able to be used fo...
|
|
WO/2018/219278A1 |
This invention provides a method for preparing CAR-T cells, comprising: providing cells comprising a chimeric antigen receptor; and culturing the cells in the presence of an agent that an extracellular domain of the CAR binds to obtain C...
|
|
WO/2018/222891A1 |
The present disclosure provides methods of generating recombinant bacteriophage genomes. Specifically, the present technology provides methods of integrating a heterologous nucleic acid sequence into a linear bacteriophage DNA genome, an...
|
|
WO/2018/218332A1 |
In an aspect, there is provided, a method of capturing a population of T-Cell receptor and/or immunoglobulin sequences with variable regions within a patient sample, said method comprising: extracting/preparing DNA fragments from the pat...
|
|
WO/2018/220034A1 |
The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA expression is beneficial for a range of medical disorders, such...
|
|
WO/2018/220116A1 |
Provided herein are recombinant host cells having a heterologous polynucleotide encoding a xylose isomerase, wherein the cells are capable of improved growth on xylose. Also described are processes of fermenting saccharified material usi...
|
|
WO/2018/220154A1 |
The present invention relates to tetramolecular parallel G-quadruplex- forming oligonucleotides. If G-quadruplexes are of prime importance in biology, their use is hampered by the propensity of G4-prone DNA molecules, in particular G4-pr...
|
|
WO/2018/222925A1 |
This invention provides a range of translatable polynucleotide and oligomer molecules for expressing a human phenylalanine hydroxylase (PAH), or a fragment thereof having PAH activity. The polynucleotide and oligomer molecules are expres...
|
|
WO/2018/220371A1 |
The disclosure relates to the assembly of Virus Like Particles [VLPs] using packaging native and artificial packaging signals and their use in vaccines and immunological compositions and the methods of vaccination or immunisation against...
|
|
WO/2018/218879A1 |
Provided is a CAR‑T therapeutic vector based on OCTS technology, comprising a lentiviral backbone plasmid, a human EF1α promoter, and an OCTS chimeric receptor domain. The OCTS chimeric receptor domain comprises a CD8 leader chimeric ...
|
|
WO/2018/222792A1 |
The invention relates to synthetic liver-specific promoters and expression constructs for producing polypeptides and functional nucleic acids in the liver of a subject. The invention further relates to optimized polynucleotide sequences ...
|
|
WO/2018/222503A1 |
The present disclosure provides recombinant adeno-associated virus (AAV) virions with altered capsid protein, where the recombinant AAV (rAAV) virions exhibit greater infectivity of a cardiac cell compared to wild-type AAV, and where the...
|
|
WO/2018/218710A1 |
Provided are chimeric antigen receptor cells targeting ROBO1, in particular, enhanced CAR-T cells and CAR-NK cells targeting ROBO1, and preparation and application thereof. The cells can stably expressing CAR elements, while secreting ex...
|
|
WO/2018/222941A1 |
Methods for preparing concatenated nucleic acid molecules are provided. The methods herein include adaptors with complementary sequences for preparation of concatenated nucleic acid molecules, and methods of sequencing such nucleic acids.
|
|
WO/2018/221680A1 |
The present invention relates to: a protein molded article containing an ionic liquid inside the protein molded article; a method for producing a protein molded article comprising a step for causing the molding material for a protein mol...
|
|
WO/2018/223119A1 |
This invention is directed towards genetically engineered cells, methods of making genetically engineered cells, and methods of using the same.
|
|
WO/2018/223094A1 |
Provided herein, are methods of treating cancer in dogs using personalized cancer vaccines comprising peptides having frameshift mutations caused by errors in transcription and splicing of an mRNA.
|
|
WO/2018/222667A1 |
The present technology provides targeted genome engineering (also known as genome editing) techniques to modify nicotine biosynthesis. In particular, the present technology relates to the use of genome editing methods to generate mutatio...
|
|
WO/2018/219299A1 |
Disclosed herein are methods of treating a subject exhibiting a cell that expresses Wilms tumor protein 1 (WT1). The methods typically utilize anti-WT1 antigen binding units or chimeric antigen receptor immunoresponsive cells to a subjec...
|
|
WO/2018/219301A1 |
Disclosed is a tumor necrosis factor-related apoptosis-inducing ligand variant, which is a fusion protein of a tumor necrosis factor-related apoptosis-inducing ligand and ZPDGFRβ. ZPDGFRβ is connected to the N-terminus or C-terminus of...
|
|
WO/2018/221954A1 |
The present disclosure relates to a method of delivering target materials into extracellular vesicles including exposing the target materials and the extracellular vesicles to extracorporeal shockwaves, a method of preparing target mater...
|
|
WO/2018/221521A1 |
The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives o...
|
|
WO/2018/220595A1 |
The present invention relates to a method for increasing the expression and/or promoting correct folding of a heterologous polypeptide of interest in a plant cell, comprising co-expressing the heterologous polypeptide of interest with a ...
|
|
WO/2018/218876A1 |
Provided is a lymphoblastic leukaemia CAR-T therapeutic vector based on OCTS technology, comprising a lentiviral skeleton plasmid, a human EF1α promoter, an OCTS chimeric receptor structural domain and IL6R single chain antibodies, the ...
|
|
WO/2018/223093A1 |
Disclosed herein are compositions comprising a universal cancer vaccine and methods of treating and preventing cancer using such compositions.
|
|
WO/2018/218877A1 |
Provided is a malignant glioma CAR-T therapeutic vector based on OCTS technology, comprising a lentiviral skeleton plasmid, a human EF1α promoter (SEQ ID NO. 14), an OCTS chimeric receptor structural domain and PDL1 single chain antibod...
|
|
WO/2018/220623A1 |
Disclosed is a three-dimensional (3D) cell cluster comprising transdifferentiated adult mammalian non-pancreatic beta cells having a mature pancreatic beta cell phenotype and function, wherein the transdifferentiated cells have an enhanc...
|
|
WO/2018/220582A1 |
Nucleic acid constructs for use in a method of selecting cells comprising a genome editing event, the method comprising (a) transforming cells of a plant of interest with the nucleic acid construct; (b) selecting transformed cells exhibi...
|
|
WO/2018/219093A1 |
The invention discloses a method for constructing a Glrx1 gene knock-out animal model based on CRISPR/Cas9, comprising the steps of: 1. selection and design of sgRNA targeting Glrx1 gene of mice; 2. construction of an sgRNA vector; 3. in...
|
|
WO/2018/222548A1 |
The present disclosure provides a method for amplifying RNA using a combination of reverse transcription and multiple annealing and looping based amplification cycles. Primers are used such that the resulting amplicons include a first ce...
|
|
WO/2018/220185A1 |
The application discloses circRNAs as new biomarkers for the diagnosis of heart failure, the prediction of the clinical evolution of heart failure and/or prediction of the response to a treatment in a patient; methods for the prediction ...
|
|
WO/2018/219995A1 |
A yeast comprising a nucleotide sequence expression system expressing a synthetic Calvin cycle comprising heterologous genes, which include at least a) a gene encoding an enzyme from the class of the ribulose-bisphosphate carboxylases (E...
|
|
WO/2018/223073A1 |
Among other things, the present disclosure provides designed APOC3 oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or R...
|
|
WO/2018/218476A1 |
The present invention provides use of a manganese peroxidase in the detoxification of mycotoxins, and specifically, the present invention provides five manganese peroxidases (MnP-1, MnP-2, MnP-4, MnP-5, and MnP-6), genes thereof, and use...
|
|
WO/2018/218875A1 |
Provided is a prostate cancer CAR-T therapeutic vector targeting both PSMA and PDL1, comprising a lentiviral backbone plasmid, a human EF1α promoter, a double targeting chimeric receptor domain, and a PDL1 single-chain antibody. The dou...
|
|
WO/2018/222986A1 |
The disclosed compositions and methods provide an approach for the rational development of a nucleic acid vaccine. Methods are disclosed to deliver a viral genome, and/or a representative or derivative of such, that is attenuated but can...
|
|
WO/2018/220929A1 |
This expression system comprises: a first nucleic acid fragment including Long Intergenic Region (LIR) derived from a gemini virus, Small Intergenic Region (SIR) derived from a gemini virus, and an expression cassette of a target protein...
|
|
WO/2018/218299A1 |
The present invention relates to transgenic avians and the eggs produced therefrom wherein the eggs comprise a genetic modification that facilitates in ovo gender sorting and a genetic modification that increases a production trait in th...
|
|
WO/2018/221240A1 |
Provided is a QProbe by which costs for fluorescent labeling are lowered. When a nucleic acid probe labeled with a fluorochrome hybridizes to a target nucleic acid, the fluorochrome decreases fluorescent emission. The 5'-end region of sa...
|
|
WO/2018/218857A1 |
Provided are a MYH4 gene molecule marker for improved pork quality and use thereof in porcine genetic improvement. The molecule marker comprises at least one of: (I) a nucleotide Y at site 11031 from the 5' end of SEQ ID No. 1; (II) a nu...
|
|
WO/2018/218360A1 |
An immunogenic polypeptide selected from an isolated Clostridium perfringens pilus polypeptide, a variant of the pilus polypeptide; a fragment of the pilus polypeptide; and a fragment of the variant, is useful for the preparation of a va...
|
|
WO/2018/219327A1 |
Provided are an anti-CD40 antibody, an antigen binding fragment thereof, and a medical use thereof. Also provided are a chimeric antibody and a humanized antibody including a CDR region of the anti-CD40 antibody, a pharmaceutical composi...
|
|
WO/2018/221649A1 |
The present invention provides double-stranded nucleic acids that suppress the expression of the APCS gene, the double-stranded nucleic acids comprising sense-strand nucleic acids and antisense-strand nucleic acids, and including an at l...
|
